NCT03028415已完成不适用
A Multi-Center, Randomized, Pivotal Study Evaluating AMPLEX Compared To Autogenous Bone Graft in Subjects Indicated for Arthrodesis Surgery Involving the Hindfoot or Ankle
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 72
- 主要终点
- Proportion of Subjects Who Met All Five Criteria for Subject Performance Composite (SPC) Endpoint
研究概览
简要总结
To demonstrate that AMPLEX is non-inferior to autogenous bone graft (ABG) for bone fusion in a population indicated for single, double, or triple hindfoot arthrodesis or ankle arthrodesis surgery with supplemental graft material.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 74 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed written informed consent
- •Indicated for ankle or hindfoot arthrodesis and require one of the following arthrodesis procedures:
- •Tibiotalar (ankle); Talocalcaneal (subtalar); Talonavicular; Calcaneocuboid; Double hindfoot (e.g., talonavicular and talocalcaneal joints); Triple hindfoot (subtalar, talonavicular and calcaneocuboid joints)
- •Presents with pain on weight-bearing of at least 40 mm on a 100 mm VAS at the area indicated for arthrodesis
- •Presents with at least one comorbid risk factors that warrant the use of supplemental autogenous bone or allograft:
- •Radiographic evidence of bone defect, deficit, subsidence or subchondral cyst; More than one joint to be fused; Involvement of other adjacent or nonadjacent joints; Large surface area; Intra-articular or extra-articular deformity; Post-traumatic arthritis; Diagnosis of osteoporosis
- •The Investigator determines if the joint space(s) can be adequately filled with graft material (AMPLEX or ABG) according to the following parameters:
- •Single hindfoot joint fusion: up to 5 cm^3; Double or triple hindfoot fusion: each individual joint up to 5 cm^3, but overall, not more than 10 cm3 for the full complement of joints; Ankle fusion: up to 10 cm^3
- •Each fused joint can be rigidly stabilized with with at least 1 and no more than 3 screws across the fusion plane. (Supplemental pins and staples may be used, as well as supplemental screws and plates external to the fusion site(s))
- •Willing and able to comply with all study requirements including all postoperative clinical and radiographic evaluations
- •For women of childbearing potential (not post-menopausal for 12 months or surgically sterile), a urine pregnancy test with a negative result must be obtained at screening and within 24 hours prior to procedure. These trial participants must commit to adequate birth control (e.g., oral contraceptive, two methods of barrier birth control, or abstinence) through the 78 week follow-up
排除标准
- •Bone deficit requiring a structural graft
- •Charcot foot disease
- •Radiographic evidence of open physes
- •Prior arthroplasty, arthrodesis, major surgical repair or reconstruction of the index ankle or hindfoot joint(s)
- •Requires osteotomy or fusion of the midfoot joints
- •BMI greater than 45 kg/m^2
- •Documented medical history of, or radiographic evidence of, a bone disease (e.g. avascular necrosis) or other condition (e.g., osteolysis) that would preclude the subject from receiving screw fixation in the opinion of the surgeon
- •Requires intramedullary nail fixation or an external fixator
- •Comorbidity that would limit the ability to administer any functional measurements such as FAAM-ADL
- •Has at the time of surgery, a systemic infection or local infection at the site of surgery
- •Medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the Investigator, would preclude participation in the study or potentially decrease survival or interfere with ambulation or rehabilitation (e.g., history of transient ischemic attack, stroke or liver disease)
- •HgbA1c level greater than or equal to 8%
- •Known hypersensitivity to any of the components of the product [e.g. B2A peptide, Hydroxyapatite (HA): beta-tricalcium phosphate (βTCP), ceramic granule]
- •Currently receiving treatment with a drug known to interfere with bone metabolism [e.g., systemic corticosteroid therapy (topical corticosteroid therapy is permissible), methotrexate]
- •Has previously received treatment with a drug known to interfere with bone metabolism [e.g., systemic corticosteroid therapy (topical corticosteroid therapy is permissible), methotrexate] and in the opinion of the investigator could continue to negatively interfere with bone metabolism or bone healing
- •History of any severe allergy or anaphylaxis, or a history of hypersensitivity to protein pharmaceuticals [e.g., monoclonal antibodies or gamma globulins, recombinant Bone Morphogenetic Proteins (BMPs)]
- •Medical condition requiring radiation, chemotherapy or immunosuppression
- •Have a prior or active history of malignancy (except for basal cell carcinoma of the skin)
- •Has a history of autoimmune disease known to affect bone metabolism. Examples include spondyloarthropathies (e.g., ankylosing spondylitis, Crohn's disease, and ulcerative colitis), Juvenile Arthritis, Grave's disease and Hashimoto's thyroiditis; Rheumatoid Arthritis is allowed
- •Have pathological or genetic liver disease or who have clinically significant, elevated baseline liver function enzymes
- •Has obvious and/or documented alcohol or illicit drug addictions
- •Is a prisoner in a correctional institution/facility
- •Actively involved in litigation or workman's compensation
- •Has participated in clinical studies evaluating investigational devices, pharmaceuticals or biologics within 6 months of randomization
- •Requires chronic therapeutic use of NSAID during the first 6 post-operative weeks (except aspirin up to 325 mg bid for cardiovascular protection and/or DVT prophylaxis)
- •Has previously been treated with, or exposed to, therapeutic levels of synthetic or recombinant BMPs
- •Requires chronic subcutaneous or intravenous heparin therapies
结局指标
主要结局
Proportion of Subjects Who Met All Five Criteria for Subject Performance Composite (SPC) Endpoint
时间窗: At week 52
Proportion of subjects who met all the following criteria for the SPC endpoint at 52 weeks: 1. Improvement in pain on weight-bearing at fusion site (≥20 mm reduction from baseline on 100 mm visual analog scale \[VAS\]); 2. Absence of significant graft harvest site pain (\<20 mm on 100 mm VAS); 3. Improvement in Foot and Ankle Ability Measure Activities of Daily Living subscale (FAAM-ADL) (≥8 points improvement from baseline); 4. Absence of device related or procedure related serious adverse events (up to week 52); 5. Absence of secondary surgical or nonsurgical interventions intended to promote fusion (up to week 52). The last observation carried forward was used for subjects with missing response status at 52 weeks.
次要结局
- Proportion of Subjects Achieving Computerized Tomography (CT) Radiographic Fusion Success(At week 52)
- Proportion of Subjects Achieving CT Radiographic Fusion Success(At week 24)
- Proportion of Subjects With Change From Baseline in Pain on Weight-bearing at Fusion Site (>20 mm Reduction From Baseline on 100 mm VAS)(Baseline, and at week 52)
- Change From Baseline in FAAM-ADL(Baseline, and at week 52)
- Change From Baseline in Short Form-12 (SF-12)(Baseline, and at week 52)
- Proportion of Subjects With Absence of Graft Harvest Site Pain (<20 mm on 100 mm VAS)(At week 52)
- Subject Performance Composite (SPC) Endpoint(At week 24)
研究者
研究点 (72)
Loading locations...
相似试验
终止
4 期
Comparison of Actifuse ABX and Local Bone in Spinal SurgeryKyphosisLordosisScoliosisNCT01852747Ohio State University14
已完成
不适用
Autobone and Bioactive Glass With Ridge SplittingHorizontal Alveolar Ridge DeficiencyNCT04814160Kafrelsheikh University22
已完成
1 期
Safety Study of Mesenchymal Stem Cells and Spinal FusionLumbar Spondylolisthesis Involving L4-L5, and/orDegenerative Discopathy Involving L4-L5NCT01552707Banc de Sang i Teixits69
已完成
不适用
An evaluation of alloplastic and xenograft in intrabony defects.CTRI/2018/04/013070ch sandhya sree24
已完成
不适用
The effect of bone graft use with low-level laser therapy in the treatment of periodontal diseaseChronic periodontitis.Chronic pericoronitisIRCT201207019121N2Tabriz university of medical sciences15